Characteristics of SARS-CoV-2 Infection in an Actively Monitored Cohort of Patients with Lupus Nephritis
(1) Background: We sought to investigate the impact of the COVID-19 pandemic in patients with lupus nephritis (LN); (2) Methods: A total of 95 patients with LN actively monitored in our department between 26 February 2020, when the first case of COVID-19 was diagnosed in Romania, and 1 May 2021, wer...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/10/2423 |
| _version_ | 1797475078898712576 |
|---|---|
| author | Bogdan Obrișcă Alexandra Vornicu Roxana Jurubiță Valentin Mocanu George Dimofte Andreea Andronesi Bogdan Sorohan Camelia Achim Georgia Micu Raluca Bobeică Constantin Dina Gener Ismail |
| author_facet | Bogdan Obrișcă Alexandra Vornicu Roxana Jurubiță Valentin Mocanu George Dimofte Andreea Andronesi Bogdan Sorohan Camelia Achim Georgia Micu Raluca Bobeică Constantin Dina Gener Ismail |
| author_sort | Bogdan Obrișcă |
| collection | DOAJ |
| description | (1) Background: We sought to investigate the impact of the COVID-19 pandemic in patients with lupus nephritis (LN); (2) Methods: A total of 95 patients with LN actively monitored in our department between 26 February 2020, when the first case of COVID-19 was diagnosed in Romania, and 1 May 2021, were included in the study. Multivariate logistic regression analysis was performed to identify the independent risk factors for SARS-CoV-2 infection; (3) Results: A total of 15 patients (15.8%) had a confirmed SARS-CoV-2 infection during a total follow-up time of 105.9 patient-years (unadjusted incidence rate: 14.28 SARS-CoV-2 infections per 100 patient-years). Median time to SARS-CoV-2 infection was 9.3 months (IQR: 7.2–11.3). The majority of patients had a mild form of SARS-CoV-2 infection (73.3%), while the remaining had moderate forms. None of the patients had a severe infection or a SARS-CoV-2-related death. The most frequent symptom was fatigue (73.3%), followed by loss of taste/smell (53.3%) and fever (46.7%). Forty percent of those with SARS-CoV-2 infection were hospitalized for a median 11.5 days (IQR:3.75–14). In the multivariate logistic regression analysis, a current oral corticosteroid dose ≥ 15 mg/day was associated with a 7.69-fold higher risk (OR, 7.69; 95%, 1.3–45.46), while the use of hydroxychloroquine was associated with a 91% lower risk for a SARS-CoV-2 infection (OR, 0.09; 95%CI, 0.01–0.59). (4) Conclusions: Our study confirms that the SARS-CoV-2 infection-associated morbidity might only be moderately increased in patients with LN. The current oral corticosteroid dose was the only independent predictor of infection occurrence, while use of hydroxychloroquine was associated with a protective effect. |
| first_indexed | 2024-03-09T20:39:04Z |
| format | Article |
| id | doaj.art-895f62b704754fc894d102a9d1a24595 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T20:39:04Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-895f62b704754fc894d102a9d1a245952023-11-23T23:02:49ZengMDPI AGBiomedicines2227-90592022-09-011010242310.3390/biomedicines10102423Characteristics of SARS-CoV-2 Infection in an Actively Monitored Cohort of Patients with Lupus NephritisBogdan Obrișcă0Alexandra Vornicu1Roxana Jurubiță2Valentin Mocanu3George Dimofte4Andreea Andronesi5Bogdan Sorohan6Camelia Achim7Georgia Micu8Raluca Bobeică9Constantin Dina10Gener Ismail11Department of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, RomaniaDepartment of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, RomaniaDepartment of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, RomaniaDepartment of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, RomaniaDepartment of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, RomaniaDepartment of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, RomaniaDepartment of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, RomaniaDepartment of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, RomaniaDepartment of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, RomaniaDepartment of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, RomaniaDepartment of Anatomy, Ovidius University, 900470 Constanța, RomaniaDepartment of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, Romania(1) Background: We sought to investigate the impact of the COVID-19 pandemic in patients with lupus nephritis (LN); (2) Methods: A total of 95 patients with LN actively monitored in our department between 26 February 2020, when the first case of COVID-19 was diagnosed in Romania, and 1 May 2021, were included in the study. Multivariate logistic regression analysis was performed to identify the independent risk factors for SARS-CoV-2 infection; (3) Results: A total of 15 patients (15.8%) had a confirmed SARS-CoV-2 infection during a total follow-up time of 105.9 patient-years (unadjusted incidence rate: 14.28 SARS-CoV-2 infections per 100 patient-years). Median time to SARS-CoV-2 infection was 9.3 months (IQR: 7.2–11.3). The majority of patients had a mild form of SARS-CoV-2 infection (73.3%), while the remaining had moderate forms. None of the patients had a severe infection or a SARS-CoV-2-related death. The most frequent symptom was fatigue (73.3%), followed by loss of taste/smell (53.3%) and fever (46.7%). Forty percent of those with SARS-CoV-2 infection were hospitalized for a median 11.5 days (IQR:3.75–14). In the multivariate logistic regression analysis, a current oral corticosteroid dose ≥ 15 mg/day was associated with a 7.69-fold higher risk (OR, 7.69; 95%, 1.3–45.46), while the use of hydroxychloroquine was associated with a 91% lower risk for a SARS-CoV-2 infection (OR, 0.09; 95%CI, 0.01–0.59). (4) Conclusions: Our study confirms that the SARS-CoV-2 infection-associated morbidity might only be moderately increased in patients with LN. The current oral corticosteroid dose was the only independent predictor of infection occurrence, while use of hydroxychloroquine was associated with a protective effect.https://www.mdpi.com/2227-9059/10/10/2423lupus nephritisSARS-CoV-2 infectioncorticosteroidshydroxychloroquine |
| spellingShingle | Bogdan Obrișcă Alexandra Vornicu Roxana Jurubiță Valentin Mocanu George Dimofte Andreea Andronesi Bogdan Sorohan Camelia Achim Georgia Micu Raluca Bobeică Constantin Dina Gener Ismail Characteristics of SARS-CoV-2 Infection in an Actively Monitored Cohort of Patients with Lupus Nephritis Biomedicines lupus nephritis SARS-CoV-2 infection corticosteroids hydroxychloroquine |
| title | Characteristics of SARS-CoV-2 Infection in an Actively Monitored Cohort of Patients with Lupus Nephritis |
| title_full | Characteristics of SARS-CoV-2 Infection in an Actively Monitored Cohort of Patients with Lupus Nephritis |
| title_fullStr | Characteristics of SARS-CoV-2 Infection in an Actively Monitored Cohort of Patients with Lupus Nephritis |
| title_full_unstemmed | Characteristics of SARS-CoV-2 Infection in an Actively Monitored Cohort of Patients with Lupus Nephritis |
| title_short | Characteristics of SARS-CoV-2 Infection in an Actively Monitored Cohort of Patients with Lupus Nephritis |
| title_sort | characteristics of sars cov 2 infection in an actively monitored cohort of patients with lupus nephritis |
| topic | lupus nephritis SARS-CoV-2 infection corticosteroids hydroxychloroquine |
| url | https://www.mdpi.com/2227-9059/10/10/2423 |
| work_keys_str_mv | AT bogdanobrisca characteristicsofsarscov2infectioninanactivelymonitoredcohortofpatientswithlupusnephritis AT alexandravornicu characteristicsofsarscov2infectioninanactivelymonitoredcohortofpatientswithlupusnephritis AT roxanajurubita characteristicsofsarscov2infectioninanactivelymonitoredcohortofpatientswithlupusnephritis AT valentinmocanu characteristicsofsarscov2infectioninanactivelymonitoredcohortofpatientswithlupusnephritis AT georgedimofte characteristicsofsarscov2infectioninanactivelymonitoredcohortofpatientswithlupusnephritis AT andreeaandronesi characteristicsofsarscov2infectioninanactivelymonitoredcohortofpatientswithlupusnephritis AT bogdansorohan characteristicsofsarscov2infectioninanactivelymonitoredcohortofpatientswithlupusnephritis AT cameliaachim characteristicsofsarscov2infectioninanactivelymonitoredcohortofpatientswithlupusnephritis AT georgiamicu characteristicsofsarscov2infectioninanactivelymonitoredcohortofpatientswithlupusnephritis AT ralucabobeica characteristicsofsarscov2infectioninanactivelymonitoredcohortofpatientswithlupusnephritis AT constantindina characteristicsofsarscov2infectioninanactivelymonitoredcohortofpatientswithlupusnephritis AT generismail characteristicsofsarscov2infectioninanactivelymonitoredcohortofpatientswithlupusnephritis |